Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT

Study summary

This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT) in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or cancer that has spread to the liver (metastatic) that can not be removed by surgery. Imaging procedures, such as PET/CT after Yttrium-90 bead therapy, may help see if the beads are present in the lung and compare the results with the pre-therapy imaging.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedpositron emission tomography and computed tomography

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable · Metastatic or stage IV · Recurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 11, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Cincinnati

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Cincinnati
Interventions being studied: Procedure: positron emission tomography; Procedure: computed tomography

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Early-stage or resectable→Metastatic or stage IV→Recurrent or relapsed→

Treatment approach

Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients who undergo intra-arterial hepatic 99mTc MAA evaluation in anticipation of 90Y microsphere radioembolization

Reasons someone may not be able to joinExclusion criteria

Patients who are unable to give consent
Prisoners

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical CenterColumbus, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 11, 2025. Always confirm current availability with the study team.

View original record ↗